AU2004269979B2 - Design of re-targeted toxin conjugates - Google Patents

Design of re-targeted toxin conjugates Download PDF

Info

Publication number
AU2004269979B2
AU2004269979B2 AU2004269979A AU2004269979A AU2004269979B2 AU 2004269979 B2 AU2004269979 B2 AU 2004269979B2 AU 2004269979 A AU2004269979 A AU 2004269979A AU 2004269979 A AU2004269979 A AU 2004269979A AU 2004269979 B2 AU2004269979 B2 AU 2004269979B2
Authority
AU
Australia
Prior art keywords
protease
target cell
agonist
lhn
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004269979A
Other languages
English (en)
Other versions
AU2004269979A1 (en
Inventor
John Chaddock
Keith Foster
Charles Penn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Bioinnovation Ltd
Original Assignee
Ipsen Bioinnovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd filed Critical Ipsen Bioinnovation Ltd
Publication of AU2004269979A1 publication Critical patent/AU2004269979A1/en
Assigned to SYNTAXIN LIMITED reassignment SYNTAXIN LIMITED Request for Assignment Assignors: HEALTH PROTECTION AGENCY
Application granted granted Critical
Publication of AU2004269979B2 publication Critical patent/AU2004269979B2/en
Assigned to IPSEN BIOINNOVATION LIMITED reassignment IPSEN BIOINNOVATION LIMITED Request to Amend Deed and Register Assignors: SYNTAXIN LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2004269979A 2003-09-11 2004-09-13 Design of re-targeted toxin conjugates Ceased AU2004269979B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0321344.4 2003-09-11
GBGB0321344.4A GB0321344D0 (en) 2003-09-11 2003-09-11 Re-targeted toxin conjugates
PCT/GB2004/003904 WO2005023309A2 (en) 2003-09-11 2004-09-13 Design of re-targeted toxin conjugates

Publications (2)

Publication Number Publication Date
AU2004269979A1 AU2004269979A1 (en) 2005-03-17
AU2004269979B2 true AU2004269979B2 (en) 2009-12-10

Family

ID=29226936

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004269979A Ceased AU2004269979B2 (en) 2003-09-11 2004-09-13 Design of re-targeted toxin conjugates

Country Status (7)

Country Link
US (4) US20070184048A1 (https=)
EP (1) EP1667725A2 (https=)
JP (2) JP2007505094A (https=)
AU (1) AU2004269979B2 (https=)
CA (1) CA2538619C (https=)
GB (1) GB0321344D0 (https=)
WO (1) WO2005023309A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
HK1046020B (en) 1999-08-25 2007-05-11 Allergan, Inc. Activatable recombinant neurotoxins
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
PL1830872T3 (pl) 2004-12-01 2011-09-30 Sec Dep For Health Białka fuzyjne
PL1877073T3 (pl) * 2004-12-01 2014-03-31 The Sec Dep For Health Niecytotoksyczne koniugaty białkowe
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1871789B1 (en) 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
GB0610868D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
EP2505592A1 (en) 2006-07-11 2012-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
WO2009020748A2 (en) * 2007-07-16 2009-02-12 Avaxia Biologics, Inc. Antibody therapy for modulating function of intestinal receptors
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
EP2211890A1 (en) * 2007-10-23 2010-08-04 Allergan, Inc. Methods of treating urogenital-neurological disorders using modified clostridial toxins
GB0803068D0 (en) 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
GB0903006D0 (en) 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
ES2770033T3 (es) 2009-03-13 2020-06-30 Allergan Inc Ensayos de actividad de endopeptidasa redirigida basados en inmunología
KR20120061053A (ko) * 2009-08-27 2012-06-12 시냅틱 리서치, 엘엘씨 유도 만능 줄기(ｉＰＳ) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템
KR20120107988A (ko) 2009-12-16 2012-10-04 알러간, 인코포레이티드 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소
SI2684890T1 (sl) 2010-01-25 2016-10-28 Allergan, Inc. Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko
RU2561465C2 (ru) 2010-05-20 2015-08-27 Аллерган, Инк. Разрушаемые клостридиальные токсины
US20130330369A1 (en) 2010-10-08 2013-12-12 Allergan, Inc. Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201219024D0 (en) * 2012-10-23 2012-12-05 Syntaxin Ltd Assay
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0467536A2 (en) * 1990-06-21 1992-01-22 Merck & Co. Inc. Method of treating bladder cancer cells
WO1994021300A2 (en) * 1993-03-19 1994-09-29 Speywood Lab Ltd Novel agent for controlling cell activity
WO1998007864A1 (en) * 1996-08-23 1998-02-26 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Recombinant toxin fragments
WO1999058571A2 (de) * 1998-05-13 1999-11-18 BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
US20030059912A1 (en) * 1998-05-13 2003-03-27 Biotecon Gesellschaft Fur Biotechnologische Entwicklung Und Consulting Mbh Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
EP2351838A1 (en) * 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Crosslinking agonistic antibodies
EP1327681A4 (en) * 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0467536A2 (en) * 1990-06-21 1992-01-22 Merck & Co. Inc. Method of treating bladder cancer cells
WO1994021300A2 (en) * 1993-03-19 1994-09-29 Speywood Lab Ltd Novel agent for controlling cell activity
WO1998007864A1 (en) * 1996-08-23 1998-02-26 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Recombinant toxin fragments
WO1999058571A2 (de) * 1998-05-13 1999-11-18 BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
US20030059912A1 (en) * 1998-05-13 2003-03-27 Biotecon Gesellschaft Fur Biotechnologische Entwicklung Und Consulting Mbh Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ABDULLA, P. et al., FASEB J. Vol. 11, no. 3, 1997, page A516 (XY) *
CAIN, C.C. et al., J. Biol. Chem. 1992, vol. 267, no. 17, pages 11681-84 (X) *
DAVIS, R. J. et al., J. Biol. Chem. 1987, vol. 262, no. 27, pages 13126-34 (X) *
DEBINSKI, W. et al., J. Biol. Chem. 1995, vol. 270, no. 28, pages 16775-80 (XY) *
ENSS, M-L. et al., Gastroenterology, 1998, vol. 114, no. 4, part 2, page A973 (XY) *
ENSS, M-L. et al., Inflammation Res. 2000, Vol. 49, no. 4, pages 162-169 (XY) *
JAYAWICKREME, S. P. et al., Am. J. Physiol.-Lung Cellular and Mol. Physiol. 1999, vol. 276, no. 4, pages L596-L603 (XY) *
LI, Dailin et al., J. Biol. Chem. 2001, vol. 276, no. 25, pages 22883-91(X) *
OLSON, A.L. et al., J. Biol. Chem. 2001, vol. 276, no. 14, pages 10706-714 (X) *
SKEBERDIS, V. A. et al., PNAS. 2001, vol. 98, no. 6, pages 3561-66 (XY) *
YANG, Chun Zhi et al., J. Biol. Chem. 1999, vol. 274, no. 36, pages 25297-300 (X) *

Also Published As

Publication number Publication date
WO2005023309A2 (en) 2005-03-17
GB0321344D0 (en) 2003-10-15
JP6122243B2 (ja) 2017-04-26
JP2012139222A (ja) 2012-07-26
US20070184048A1 (en) 2007-08-09
AU2004269979A1 (en) 2005-03-17
CA2538619C (en) 2012-10-16
WO2005023309A3 (en) 2005-09-15
CA2538619A1 (en) 2005-03-17
US20180362951A1 (en) 2018-12-20
EP1667725A2 (en) 2006-06-14
JP2007505094A (ja) 2007-03-08
US20130122526A1 (en) 2013-05-16
US20090291457A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
AU2004269979B2 (en) Design of re-targeted toxin conjugates
JP6027035B2 (ja) 非細胞傷害性タンパク質結合体
AU782457B2 (en) Inhibition of secretion from non-neuronal cells
AU2005311098B2 (en) Non-cytotoxic protein conjugates
US8852603B2 (en) Inhibition of secretion from non-neuronal cells
US20080152667A1 (en) Methods and compounds for the treatment of mucus hypersecretion
US9012195B2 (en) Non-cytotoxic protein conjugates
US8603779B2 (en) Non-cytotoxic protein conjugates
US10619146B2 (en) Non-cytotoxic protein conjugates
WO2007138336A2 (en) Treatment of pain by single chain, polypeptide fusion protein

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SYNTAXIN LIMITED

Free format text: FORMER APPLICANT(S): HEALTH PROTECTION AGENCY

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: IPSEN BIOINNOVATION LIMITED

Free format text: FORMER NAME(S): SYNTAXIN LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired